Satellos Bioscience Inc. (MSLE)
MSLE moved a median of 0.00% 30 minutes after news, and -1.18% by the close. How MSLE actually reacts to news — the realized, point-in-time move the market made, measured across 50 labeled events over the last three years with zero look-ahead.
MSLE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 31% | 35 |
| 30-min | 0.00% | 41% | 46 |
| 60-min | -0.65% | 38% | 48 |
| to close | -1.18% | 36% | 50 |
| Middle 50% of MSLE reactions | -1.17% to +0.77% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 50 |
Half of all Satellos Bioscience Inc. news events land between -1.17% and +0.77% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MSLE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MSLE's baseline. Nothing else.
Recent MSLE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Satellos Bioscience Inc. For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | +1.18% | -4.85% | |
| Satellos Granted Composition of Matter Patent for Forazapadin | Press release | GlobeNewswire | +1.18% | -4.85% | |
| Form 6-K Satellos Bioscience Inc. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.16% | |
| Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +0.00% | -1.16% | |
| Form 6-K Satellos Bioscience Inc. For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.47% | |
| Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development | Press release | GlobeNewswire | +0.00% | +2.47% | |
| Form 6-K Satellos Bioscience Inc. For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | — | -4.29% | |
| Satellos to Present at the 31st Annual Congress of the World Muscle Society | Press release | GlobeNewswire | — | -4.29% | |
| Form 6-K Satellos Bioscience Inc. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +1.09% | +8.91% | |
| Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 | Press release | GlobeNewswire | +1.09% | +8.91% | |
| Form 6-K Satellos Bioscience Inc. For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | — | -3.51% | |
| Satellos to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | — | -3.51% | |
| Form 6-K Satellos Bioscience Inc. For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | — | +3.00% | |
| Form SUPPL Satellos Bioscience Inc. | SEC filing · Form SUPPL | SEC EDGAR | — | +3.00% | |
| Form 6-K Satellos Bioscience Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.74% | |
| Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress | Press release | GlobeNewswire | +0.00% | -1.74% | |
| Form F-10 Satellos Bioscience Inc. | SEC filing · Form F-10 | SEC EDGAR | +0.00% | -0.59% | |
| Form 6-K Satellos Bioscience Inc. For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | +2.07% | +3.22% | |
| Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 | Press release | GlobeNewswire | +2.07% | +3.22% | |
| Form 6-K Satellos Bioscience Inc. For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | +1.02% | +2.47% | |
| Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +1.02% | +2.47% | |
| Form 6-K Satellos Bioscience Inc. For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | — | +17.51% | |
| Satellos to Present Clinical Program Updates at ICNMD 2026 | Press release | GlobeNewswire | — | +17.51% | |
| Form 6-K Satellos Bioscience Inc. For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.36% | |
| Form 6-K Satellos Bioscience Inc. For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.36% | |
| Satellos Bioscience Announces Results of Annual Meeting of Shareholders | Press release | GlobeNewswire | +0.00% | -4.36% | |
| Form 6-K Satellos Bioscience Inc. For: May 27 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +4.45% | |
| Satellos to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +4.45% | |
| Form 6-K Satellos Bioscience Inc. For: May 19 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +4.77% | |
| Form 6-K Satellos Bioscience Inc. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.23% | |
| Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress | Press release | GlobeNewswire | +0.00% | -2.23% | |
| Form 6-K Satellos Bioscience Inc. For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.80% | |
| Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference | Press release | GlobeNewswire | +0.00% | -0.80% | |
| Form 40-F Satellos Bioscience Inc. For: Dec 31 | SEC filing · Form 40-F | SEC EDGAR | +0.00% | -17.25% | |
| Form 6-K Satellos Bioscience Inc. For: Mar 27 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -17.25% | |
| Form S-8 Satellos Bioscience Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -17.25% | |
| Satellos Reports 2025 Financial Results and Highlights Recent Company Progress | Press release | GlobeNewswire | +0.00% | -17.25% | |
| Form 6-K Satellos Bioscience Inc. For: Mar 10 | SEC filing · Form 6-K | SEC EDGAR | -6.25% | -26.33% | |
| Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference | Press release | GlobeNewswire | -6.25% | -26.33% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 24 | SEC filing · Form 6-K | SEC EDGAR | +0.86% | +0.63% | |
| Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference | Press release | Business Wire | +0.86% | +0.63% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 19 | SEC filing · Form 6-K | SEC EDGAR | — | -0.04% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 18 | SEC filing · Form 6-K | SEC EDGAR | — | +0.31% | |
| Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy | Press release | Business Wire | -0.35% | -2.09% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 17 | SEC filing · Form 6-K | SEC EDGAR | -0.43% | -0.61% | |
| Satellos to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.68% | -2.22% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 10 | SEC filing · Form 6-K | SEC EDGAR | +0.43% | -3.59% | |
| Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy | Press release | Business Wire | +0.43% | -3.59% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 09 | SEC filing · Form 6-K | SEC EDGAR | — | -1.18% | |
| Form 6-K Satellos Bioscience Inc. For: Feb 10 | SEC filing · Form 6-K | SEC EDGAR | — | -1.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MSLE section they belong to.
Where else MSLE is measured.
MSLE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Satellos Bioscience Inc.'s median reaction calculated?
Every labeled MSLE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 50 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of MSLE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MSLE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.